Skip to content

Identification of Key Genes and Construction of miRNA-mRNA Regulatory Networks Associated with Glioma Grade by Bioinformatics Analysis.

Oct 2026 · Current Medicinal Chemistry · Vol 33 · 0 citations
Medicine

TL;DR

The identified 16 hub genes and associated miRNA-mRNA axes point to potential molecular mechanisms underlying the malignancy of LGG into HGG and identify promising biomarkers and therapeutic targets for this devastating disease.

Abstract

INTRODUCTION The malignant transformation of Low-Grade Gliomas (LGGs) represents a critical clinical event, leading to intensified therapeutic regimens, higher morbidity, and premature death. This study aimed to identify Differentially Expressed Genes (DEGs) between LGGs and High-Grade Gliomas (HGGs) and to build a regulatory network involving microRNAs (miRNAs) and messenger RNAs (mRNAs) to explore the mechanisms driving the malignant progression of LGGs.

Methods

In this bioinformatics study, we obtained two microarray datasets, GSE30472 and GSE45921, from the Gene Expression Omnibus (GEO) database, where 24 LGG samples and 53 HGG samples from the Cancer Genome Atlas (TCGA), the Chinese Glioma Genome Atlas (CGGA), and the Human Protein Atlas (HPA) were included for analysis. After combining the datasets and correcting for batch effects, DEGs were identified. Further analyses included Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment, Protein-Protein Interaction (PPI) network construction, and key gene modeling for DEGs with specific biological phenotypes. Key genes were selected, and miRNA-mRNA regulatory networks were constructed using miRWalk 3.0, TargetScan, and miRDB. Univariate logistic regression was used to identify independent prognostic factors for cancer-specific survival, which were then used to construct the nomogram. The nomogram was validated by the concordance index (C-index), Receiver Operating Characteristic (ROC) curve, and calibration curves.

Results

A total of 16 mRNAs were found to be significantly differentially expressed (fold change >1.0, p < 0.05) between LGG and HGG samples. 16 hub genes, AADAT, ABLIM1, ACADSB, BABAM1, BCO2, BIRC5, C1QBP, CADM3, CALU, DAXX, DAZAP1, DBF4, DCTPP1, DEPDC1, AAK1, and C19orf47, were more prominently expressed in HGG than in LGG samples. Six regulatory pathways were identified, including hsa-let-7d-5p-CALU, hsa-let-7d-5p-AAK1, hsa-let-7e-5p-CALU, hsa-let-7e-5p-AAK1, hsamiR- 3666-DEPDC1, and hsa-miR-3666-AAK1, which are implicated in HGG pathogenesis. Finally, the dysregulated expression of the six regulatory miRNA-mRNA axes was validated by the data from the TCGA, CGGA, and HPA.

Discussion

The identified 16 hub genes and associated miRNA-mRNA axes (specifically, let-7d/let-7e to CALU/AAK1 and miR-3666 to DEPDC1/AAK1) point to potential molecular mechanisms underlying the malignancy of LGG into HGG and identify promising biomarkers and therapeutic targets. These findings require further functional validation in vitro and in vivo, as well as confirmation in larger clinical cohorts, to assess their causal role and clinical applicability.

Conclusion

Our research identified crucial hub genes and miRNA-mRNA regulatory pathways associated with glioma oncogenesis, shedding light on the mechanisms of malignant transformation in LGGs. Furthermore, these data may give us new insights into potential therapeutic targets for this devastating disease.

View source

Similar papers

Open access Oct 2026

Bioinformatic and Proteomic Analysis of Potential Prognostic Biomarkers of Glioblastoma

Introduction . Glioblastoma is characterized by marked molecular heterogeneity and aggressive biologic behavior, which requires reliable molecular biomarkers for prognostic stratification. The aim of this study is to identify potential prognostic biomarkers for glioblastoma through integrated bioinformatic and prote...

I. Gareev, O. Beylerli, S. Roumiantsev · 0 citations
Open access Oct 2026

Identification and Clinical Significance of Differentially Expressed Genes in the Tumour Microenvironment of Clear Cell Renal Cell Carcinoma.

OBJECTIVE To perform a bioinformatics analysis of differentially expressed genes (DEGs) in clear cell renal cell carcinoma (ccRCC), evaluate their clinical significance, and identify potential therapeutic targets for ccRCC. STUDY DESIGN An analytical study. Place and Duration of the Study: Department of Clinical Medi...

Rui-Peng Yang, Yan-Yan Guo · 0 citations
Open access Sep 2026

Identification of Key Genes and Pathways in Parkinson’s Disease Through Bioinformatics Analysis

Integrative transcriptomics identified conserved central-peripheral signatures in PD and five hub genes are candidate biomarkers/therapeutic targets, offering a systems-level framework for disease mechanisms and independent cohort validation.

Ehsan Lotfi, Arsh Ketabforoush, Fereshteh Azeditehrani et al. · 0 citations
Open access Aug 2026

Integrated bioinformatics analysis of prognostic significance and molecular regulation of mitochondrial metabolism-related genes in colorectal cancer

Background The development and progression of colorectal cancer (CRC) are closely associated with metabolic reprogramming, in which mitochondrial metabolism is critically associated with tumor cell survival and proliferation. This study aims to provide novel insights for mitochondrial metabolism-related genes (MMRGs)-b...

Xin-Yu Li, Kai Zhang, Tao-Tao Liu et al. · 0 citations
Open access Sep 2026

Identification of Candidate Biomarkers and Signaling Pathways Associated with Alzheimer’s Disease Using Bioinformatics Analysis of Next Generation Sequencing Data and Molecular Docking Studies

The GO and pathway enrichment analysis results revealed that the up regulated genes were mainly enriched in response to stimulus, cytoplasm, small molecule binding and signal transduction, whereas down regulated genes were mainly enriched in multicellular organism development, cell junction, ion binding and cardiac con...

B. Vastrad, Shivaling Pattanashetti, C. Vastrad · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.